Current adjuvant systemic therapy options include chemotherapy, endocrine therapy for hormone receptor (HR)-positive tumours, and targeted biological agents such as trastuzumab for human epidermal growth factor receptor (HER2)-positive tumours. The gene discussed is ERBB2; the disease is neoplasm.